Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries (Q34298571)

1 August 2017

title

Development and technology transfer of Haemophilus influenzae type b conjugate vaccines for developing countries (English)

1 reference

1 August 2017

main subject

Haemophilus influenzae

object named as

Haemophilus influenzae

1 reference

Michel Beurret

1

1 reference

1 August 2017

Ahd Hamidi

series ordinal

2

1 reference

1 August 2017

Hans Kreeftenberg

series ordinal

3

1 reference

1 August 2017

language of work or name

English

0 references

publication date

6 June 2012

1 reference

1 August 2017

1 reference

1 August 2017

volume

30

1 reference

1 August 2017

issue

33

1 reference

1 August 2017

page(s)

4897-4906

1 reference

Industrial-scale production of inactivated poliovirus vaccine prepared by culture of Vero cells on microcarrier

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Incidences of vaccine-preventable Haemophilus influenzae type b pneumonia and meningitis in Indonesian children: hamlet-randomised vaccine-probe trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Worldwide Haemophilus influenzae type b disease at the beginning of the 21st century: global analysis of the disease burden 25 years after the use of the polysaccharide vaccine and a decade after the advent of conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Development, evaluation and implementation of Haemophilus influenzae type b vaccines for young children in developing countries: current status and priority actions

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Access to vaccine technologies in developing countries: Brazil and India

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61,080 children. The Northern California Kaiser Permanente Vaccine Study Center Pediatrics Group.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

A randomized, prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Immunization of 2-month-old infants with protein-coupled oligosaccharides derived from the capsule of Haemophilus influenzae type b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Immunogenicity in infants of Haemophilus influenzae type B polysaccharide in a conjugate vaccine with Neisseria meningitidis outer-membrane protein

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Efficacy of Haemophilus influenzae type b conjugate vaccine PRP-T.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

A synthetic conjugate polysaccharide vaccine against Haemophilus influenzae type b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Experimental design to optimize an Haemophilus influenzae type b conjugate vaccine made with hydrazide-derivatized tetanus toxoid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

A new DTPw-HBV/Hib vaccine is immunogenic and safe when administered according to the EPI (Expanded Programme for Immunization) schedule and following hepatitis B vaccination at birth

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Immunogenicity and safety of four different doses of Haemophilus influenzae type b-tetanus toxoid conjugated vaccine, combined with diphtheria-tetanus-pertussis vaccine (DTP-Hib), in Indonesian infants.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

The immunogenicity and safety of a reduced PRP-content DTPw-HBV/Hib vaccine when administered according to the accelerated EPI schedule

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

An NMR spectroscopic identity test for the control of the capsular polysaccharide from Haemophilus influenzae type b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Quantification of polysaccharide in Haemophilus influenzae type b conjugate and polysaccharide vaccines by high-performance anion-exchange chromatography with pulsed amperometric detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Determination of free amino groups in proteins by trinitrobenzenesulfonic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

[38] The rapid determination of amino groups with TNBS

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Measurement of protein using bicinchoninic acid

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

A simple and rapid method for measuring unconjugated capsular polysaccharide (PRP) of Haemophilus influenzae type b in PRP-tetanus toxoid conjugate vaccine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

An ELISA employing a Haemophilus influenzae type b oligosaccharide-human serum albumin conjugate correlates with the radioantigen binding assay

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Safety and immunogenicity of an indigenously developed Haemophilus influenzae type b conjugate vaccine through various phases of clinical trials

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

The role of emerging manufacturers in access to innovative vaccines of public health importance

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Haemophilus influenzae type b conjugate vaccine stability: catalytic depolymerization of PRP in the presence of aluminum hydroxide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Technology transfer of Sabin-IPV to new developing country markets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Preparation and characterization of an immunogenic meningococcal group A conjugate vaccine for use in Africa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

Further studies on the immunogenicity of Haemophilus influenzae type b and pneumococcal type 6A polysaccharide-protein conjugates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2012.05.058

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1016/J.VACCINE.2012.05.058

1 reference

1 August 2017

1 reference